Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab, Bendamustine, Gemcitabine, Vinorelbine (Nivo-BeGEV) in Patients With Relapsed/Refractory Hodgkin Lymphoma

NCT05660993 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

50

Enrollment

NETWORK

Sponsor class

Conditions

Hodgkin Lymphoma

Interventions

DRUG: Nivolumab

Sponsor

National Research Center for Hematology, Russia